From the Journals

Avelumab safety compares with other checkpoint inhibitors


 

FROM CANCER

To characterize the adverse event profile of avelumab, they reviewed safety data on 1,650 patients enrolled in the solid tumor trial and 88 enrolled in the Merkel cell carcinoma trial, which included all patients in the trial who had received at least one dose of avelumab monotherapy by the cutoff date.

At the time of the analysis, 287 patients (16.5%) were continuing treatment, and 1,451 had discontinued therapy, largely because of disease progression.

Nearly all patients – 1,697 (97.6%) – had at least one adverse event of any grade or cause.

Four patients died from what investigators determined were TRAEs, including autoimmune hepatitis with peritoneal metastases and ascites in a patient with gastric cancer, liver metastases and acute liver failure in a patient with metastatic breast cancer, respiratory distress in a patient with breast cancer and multiple comorbidities, and treatment-related pneumonitis with ongoing Clostridium difficile colitis and diverticulitis not related to study treatment in a patient with urothelial carcinoma.

Recommended Reading

Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapies
MDedge ObGyn
Vaccine + chemo induce robust T-cell responses in late-stage cervical cancer
MDedge ObGyn
VIDEO: It’s too early to give up on immunotherapy for breast cancer
MDedge ObGyn
Pembrolizumab shows some activity against advanced endometrial cancer
MDedge ObGyn